People In Brief: Bayer, NPA, FTC
This article was originally published in The Tan Sheet
Dekkers gives Bayer two more years; Hilmas joins NPA; Hobbs directs Rainbow Light science; McSweeney starts at FTC; Bayer’s Mann takes WMSI chair; Archambault leads Ropack development.
You may also be interested in...
Sibyl Swift is responsible for developing and implementing NPA's educational, regulatory and compliance programs such as SSCI and the NPA Natural Standard. She also will assist members with claim reviews, substantiation and NDI notification policy.
NPA is restarting the Coalition to Preserve DSHEA on its own and other supplement industry trade groups are welcome to join. “We’re going to pick up the pace and really work to gain access the way other FDA-regulated industries do,” says NPA President Daniel Fabricant.
Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.